A Theranostic “SMART” Aptamer for Targeted Therapy of Prostate Cancer

Slides:

Advertisements

Similar presentations

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.

Advertisements

Volume 20, Issue 2, (February 2012)

Hepatic AAV Gene Transfer and the Immune System: Friends or Foes?

Volume 24, Issue 7, Pages (July 2016)

Volume 17, Issue 9, Pages (September 2009)

209. Use of Helicobacter pyroli Neutrophil Activating Protein (NAP) as an Immune- Modulatory Agent To Enhance the Efficacy of Oncolytic Adenovirus Therapy.

Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers Melinda Mata, Stephen.

Genome-editing Technologies for Gene and Cell Therapy

627. Non-Invasive, Multimodal Imaging of Microvesicles with Metabolically Biotinylated, Membrane-Bound Gaussia Luciferase Molecular Therapy Volume.

Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?

HSF1 in Translation Cancer Cell

Therapeutic Suppression of miR-4261 Attenuates Colorectal Cancer by Targeting MCC Guanming Jiao, Qi Huang, Muren Hu, Xuchun Liang, Fuchen Li, Chunling.

Volume 15, Issue 2, Pages (February 2007)

Volume 8, Issue 3, Pages (September 2003)

Volume 24, Issue 11, Pages (November 2016)

162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo

Michael W.M. Kühn, Scott A. Armstrong Cancer Cell

281. Rapid Generation of Induced Pluripotent Stem Cells (iPSCs) from the Urine of a Patient with Duchenne Muscular Dystrophy Molecular Therapy Volume.

Michael W.M. Kühn, Scott A. Armstrong Cancer Cell

Direct Conversion of Skin Cells into Blood: Alchemy or Science?

Molecular Therapy Volume 20, Pages S261-S262 (May 2012) DOI: /S (16)

Evolving Gene Therapy in Primary Immunodeficiency

Volume 20, Issue 6, Pages (June 2012)

Volume 21, Issue 6, Pages (June 2013)

Escaping the Valley of Death

Volume 26, Issue 2, Pages (February 2018)

Volume 15, Issue 11, Pages (November 2007)

Volume 25, Issue 1, Pages 5-7 (January 2017)

The Molecular Pathology of Primary Immunodeficiencies

The Other Face of Chimeric Antigen Receptors

Molecular Therapy - Nucleic Acids

A Trojan Horse for Human Immunodeficiency Virus

Volume 24, Issue 7, Pages (July 2016)

Genome-editing Technologies for Gene and Cell Therapy

Valder R Arruda, Patricia Favaro, Jonathan D Finn Molecular Therapy

Harnessing regulatory T cells for therapeutic purposes

Molecular Therapy - Nucleic Acids

Molecular Therapy Volume 20, (May 2012) DOI: /S (16)

Molecular Therapy Volume 7, Issue 5, (May 2003) DOI: /S (16)

847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach Molecular.

Designer Lipids Advance Systemic siRNA Delivery

Volume 20, Issue 6, Pages (June 2012)

133. Survival with Normal Neurological Development of the Juvenile Lethal Urea Cycle Defect Arginase Deficient Mouse with AAV Gene Therapy Molecular.

660. Bowel/Bladder Sensation and Control in Patients with Spinal Cord Injury Treated with Human Embryonic Stem Cell Therapy Geeta Shroff Molecular Therapy

Volume 21, Issue 8, Pages (August 2013)

68. Site Specific Intra-Placental Gene Transfer Corrects Fetal Growth Restriction in a Novel Mouse Model of Placental Insufficiency (PI) Molecular.

521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies Molecular Therapy Volume 22, Pages.

405. Hindlimb and Forelimb Strength Assessment in a Canine Model of X-Linked Myotubular Myopathy Following AAV-Mediated Gene Replacement Molecular.

674. Molecular, Biochemical and Biomechanical Analysis of Articular Cartilage Repaired with Genetically Modified Chondrocytes Expressing Insulin-Like.

Molecular Therapy Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)

In This Issue Molecular Therapy Volume 16, Issue 4, (April 2008)

Volume 18, Issue 5, Pages (May 2010)

372. Targeted Mutagenesis of Ubiquitin-Binding Lysine Residues on the Adeno- Associated Virus (AAV)2 Capsid Improves Its Transduction Efficiency Molecular.

521. AAV Immunotherapy Induces Functional Antigen Specific Regulatory T-Cells to a Neuroantigen: A Potential Treatment for MS Brad E. Hoffman Molecular.

Targeted Deletion of an Entire Chromosome Using CRISPR/Cas9

Volume 21, Issue 1, Pages (January 2013)

773. Detection of RNA Interference (RNAi) Mediated mRNA Cleavage in Fresh Injected Tumor Tissue from Patients in a Phase I Trial of pbi-shRNA™ Lipoplex.

740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells Molecular Therapy Volume 20, Pages S285-S286.

Volume 22, Issue 2, Pages (February 2014)

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

History of Oncolytic Viruses: Genesis to Genetic Engineering

Volume 10, Issue 6, Pages (December 2004)

86. A Highly Compact Epitope-Based Marker Suicide Gene for Safer and Easier Adoptive T-Cell Gene Therapy Molecular Therapy Volume 20, Pages S35-S36.

297. Minimally Invasive Implantation of Autologous Chondrocytes Transduced with rAAV5-IGF-I Improves Longterm Cartilage Repair in Full-Thickness Chondral.

Volume 20, Issue 6, Pages (June 2012)

Volume 163, Issue 4, (November 2015)

Volume 24, Issue 10, Pages (October 2016)

Morton J Cowan, Hans-Peter Kiem Molecular Therapy

Shirley Wong, Roderick A. Slavcev

624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results Molecular.

Presentation transcript:

A Theranostic “SMART” Aptamer for Targeted Therapy of Prostate Cancer Vittorio de Franciscis Molecular Therapy Volume 22, Issue 11, Pages 1886-1888 (November 2014) DOI: 10.1038/mt.2014.190 Copyright © 2014 American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 In vivo therapeutic efficacy of the A9g PSMA aptamer. By binding prostate-specific membrane antigen (PSMA), the A9g aptamer blocks NAALADase/glutamate carboxypeptidase II activity and inhibits PSMA-dependent cell migration and invasion in cancer cells in a mouse model of metastatic prostate cancer. Severe combined immunodeficiency mice were treated with the indicated aptamers and analyzed following injection of luciferase-expressing PSMA-positive prostate cancer cells. Modified from ref. 3. Molecular Therapy 2014 22, 1886-1888DOI: (10.1038/mt.2014.190) Copyright © 2014 American Society of Gene & Cell Therapy Terms and Conditions